The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2022

Filed:

Aug. 09, 2019
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Gregory Geba, Sparta, NJ (US);

Paula Dakin, Armonk, NY (US);

Stephen DiMartino, Scarsdale, NY (US);

Haitao Gao, Sr., Parsippany, NJ (US);

Jennifer Maloney, Hastings-on-Hudson, NY (US);

John Davis, Scarsdale, NY (US);

Catherine Stehman Breen, York, ME (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/22 (2006.01); A61P 29/00 (2006.01); A61P 25/02 (2006.01); A61P 19/02 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 39/3955 (2013.01); A61P 25/02 (2018.01); A61P 29/00 (2018.01); A61P 19/02 (2018.01); C07K 2317/565 (2013.01);
Abstract

A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.


Find Patent Forward Citations

Loading…